Education
About Us
Working with TipRanks
Follow Us
Enovis (ENOV)
NYSE:ENOV
ENOV Stock Chart & Stats
$31.49
$0.83(1.85%)
At close: 4:00 PM EST
$31.49
$0.83(1.85%)
Day’s Range― - ―
52-Week Range$25.47 - $49.83
Previous CloseN/A
Volume391.51K
Average Volume (3M)641.44K
Market Cap
$1.80B
Enterprise Value$3.35B
Total Cash (Recent Filing)$44.07M
Total Debt (Recent Filing)$1.46B
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Feb 19, 2026EPS Estimate
0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.75
Shares Outstanding57,159,800
10 Day Avg. Volume683,514
30 Day Avg. Volume641,441
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.95
Price to Sales (P/S)1.15
P/FCF Ratio-36.09
Enterprise Value/Market Cap1.86
Enterprise Value/Revenue1.53
Enterprise Value/Gross Profit2.57
Enterprise Value/Ebitda-7.27
Forecast
1Y Price Target
$51.00Price Target Upside61.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Divestiture And Strategic FocusThe divestiture sharpens ENOV's focus on its core P&R platform, positioning the company to expand margins, enhance profitability, and accelerate growth.
Positive Financial GuidanceENOV raised its FY25 guidance across revenue, organic growth, EBITDA, and EPS, supported by operational execution, FX tailwinds, and decreased expected tariff impacts.
Strong Cash Generation And ReinvestmentENOV has strong brand recognition within P&R and strong cash generation, which funds investment into the higher growth/margin Recon business.
Bears Say
Delayed Product LaunchThe next-gen ARVIS launch has been delayed by approximately 6 months to incorporate enhancements, although surgeon excitement around the platform remains high.
Organic Revenue Growth SlowdownOrganic revenue growth slowed to 5.1% in 2Q25 from 10.4% in 1Q25.
Valuation DiscrepancyENOV continues to trade at a depressed valuation, less than half the average 2025E EV/Sales multiple of its small-cap peers.
Enovis News
ENOV FAQ
What was Enovis’s price range in the past 12 months?
Enovis lowest stock price was $25.46 and its highest was $49.83 in the past 12 months.
What is Enovis’s market cap?
Enovis’s market cap is $1.80B.
When is Enovis’s upcoming earnings report date?
Enovis’s upcoming earnings report date is Feb 19, 2026 which is in 105 days.
How were Enovis’s earnings last quarter?
Enovis released its earnings results on Nov 06, 2025. The company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.649 by $0.101.
Is Enovis overvalued?
According to Wall Street analysts Enovis’s price is currently Undervalued.
Does Enovis pay dividends?
Enovis does not currently pay dividends.
What is Enovis’s EPS estimate?
Enovis’s EPS estimate is 0.84.
How many shares outstanding does Enovis have?
Enovis has 57,159,800 shares outstanding.
What happened to Enovis’s price movement after its last earnings report?
Enovis reported an EPS of $0.75 in its last earnings report, beating expectations of $0.649. Following the earnings report the stock price went up 10.714%.
Which hedge fund is a major shareholder of Enovis?
Currently, no hedge funds are holding shares in ENOV
Enovis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$51.00 (61.96% Upside)
$51.00 (61.96% Upside)
Blogger Sentiment
Bullish
ENOV Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $663.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 4.8%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.93%
12-Months-Change
Fundamentals
Return on Equity
-28.31%
Trailing 12-Months
Asset Growth
-7.73%
Trailing 12-Months
Company Description
Enovis
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
ENOV Company Deck
ENOV Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for Enovis was generally positive, with strong revenue and margin growth, successful product launches, and improved financial guidance. However, there were challenges such as delays in the Arvis product launch, flat growth in the U.S. hip and knee segment, and tariff-related headwinds. Despite these setbacks, the company's overall performance and outlook are optimistic.View all ENOV earnings summariesENOV Stock 12 Month Forecast
Average Price Target
$51.00
▲(61.96% Upside)
Technical Analysis
Enerpac Tool Group
―
Hillenbrand
―
Standex International
―
Helios Technologies
―
Xometry
―
Ownership Overview
2.16% Insiders
40.27% Mutual Funds
6.50% Other Institutional Investors
22.14% Public Companies and
Individual Investors